SKALA ALBUMIN-BILIRUBIN SEBAGAI FAKTOR PREDIKTOR KESINTASAN 3 BULAN PASIEN KARSINOMA SEL HATI SETELAH TRANSARTERIAL CHEMOEMBOLIZATION PERTAMA Penelitian Analisis Observasional Retrospektif Di RSUD Dr. Soetomo Surabaya

IR - PERPUSTAKAAN UNIVERSITAS AIRLANGGA. DAFTAR PUSTAKA. Au JS dan Frenette CT, 2015. Management of hepatocellular carcinoma: current status and future directions. Gut Liver, 9:437–48. Anderson DM. Dorland’s Illustrated Medical Dictionary. 32nd ed. Philadelphia: Saunders; 2012, 1809. Bargellini I, Bozzi E, Campani D, Carrai P, De Simone P, Pollina L, Cioni R, Filipponi F, Bartolozzi C, 2013. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CTpathologic correlation in 178 liver explants. European Journal of Radiology, 82(5):e212-8. Beard JR, Officer A, de Carvalho IA, Sadana R, Pot AM, Michel JP, LloydSherlock P, Epping-Jordan JE, Peeters G, Mahanani WR, Thiyagarajan JA, Chatterji S, 2016. The World report on ageing and health: a policy framework for healthy ageing. Lancet, 387(10033):2145–54. Bosch FX, Ribes J, Díaz M, Cléries R, 2004. Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127(5 Suppl 1):S5-S16. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C, 2008. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology, 48(1):137-45. Bruix J dan Sherman, 2011. Management of hepatocellular carcinoma: an update. Hepatology, 53(3):1020-2. Bruix J, Qin S, Merle P, Granito A, Huang Y, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, 2017. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 389: 56– 66. Burrel M, Reig M, Forner A, Barrufet M, de Lope CR, Tremosini S, 2012. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. Journal of Hepatology, 56(6):1330-5. Cabibbo G, Genco C, Di Marco V, Barbara M, Eneas M, Parisi P, Brancatelli G, Romano P, Craxı A, Camma C, 2011. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Alimentary Pharmacology & Therapeutics, 34:196–204.. 59 KARYA AKHIR. SKALA ALBUMIN-BILIRUBIN.... ANDRI PRAMANA RESTU.

IR - PERPUSTAKAAN UNIVERSITAS AIRLANGGA. 60. Campani C, Vitali A, Dragoni G, Aburas S, Arena U, Gianini EG, Trevisani F, Marra F, 2018. The ALBI and p-ALBI grades predict survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization (TACE). Digestive and Liver Disease, 50(1):42-61. Chen YL, Ko CJ, Chien SY, Chen LS, Chen ML, Chi CW, Lai HW, 2011. Tumor size as a prognostic factor in resected small hepatocellular carcinoma: a controversy revisited. Journal of Gastroenterology Hepatology, 26(5):851-7. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z, 2009. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology, 10:25– 34. Clark T, 2006. Complications of Hepatic Chemoembolization. Seminars in Interventional Radiology, 23(2):119-25. Debruyne EN, dan Delanghe JR, 2008. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. International Journal of Clinical Chemistry, 395(1-2):19-26. European Association For The Study Of The Liver dan European Organisation For Research And Treatment Of Cancer, 2012. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology, 56:908–43. El-Serag HB, 2011. Hepatocellular carcinoma. New England Journal of Medicine, 365(12):1118–27. Farag FM, Abdel-Khaleka EE, El-Gamala SA, Shabanaa HR, Amer TA, 2013. Evaluation of transarterial chemoembolization in treating hepatocellular carcinoma: a single center experience. Egypt Liver Journal, 3:41–46. Forner A, Reig M, Bruix J, 2018. Hepatocellular Carcinoma. The Lancet. (Tersedia di http://dx.doi.org/10.1016/S0140-6736(18)30010-2) Gokcan H, Savas N, Oztuna D, Moray G, Boyvat F, Haberal M, 2015. Predictors of Survival in Hepatocellular Carcinoma Patients. Annals of Transplantation, 20:596-603. Habib A, Desai K, Hickey R, Thornburg B, Lewandowski R, Salem R, 2015. Locoregional therapy of hepatocellular carcinoma. Clinical Liver Disease, 19:401-20. Hansmann J, Evers MJ, Bui JT, Lokken RP, Lipnik AJ, Gaba RC, 2017. AlbuminBilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall. KARYA AKHIR. SKALA ALBUMIN-BILIRUBIN.... ANDRI PRAMANA RESTU.

IR - PERPUSTAKAAN UNIVERSITAS AIRLANGGA. 61. Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma. Journal of Vascular Intervention Radiology, 28(9):1224-31.e2. Hasegawa K, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y, 2013. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. Journal of Hepatology, 58:724–29. Ho SY, Liu PH, Hsu CY, Hsia CY, Lee YH, Lee RC, 2017. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS ONE, 12(7):e0180408. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, 2015. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade. Journal of Clinical Oncology, 33(6):550-8. Kementerian Kesehatan RI, 2013. Riset Kesehatan Dasar 2013. Jakarta: Badan Penelitian dan Pengembangan Kesehatan. Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, 2014. Radiologic response to trans catheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Cancer, 34(2):305-12. Kohla MAS, Abu Zeid MI, Al-Warraky M, Taha H, Gish RG, 2015. Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. BMJ Open Gastroenterology, 2:e000032. Lencioni R, 2012. Chemoembolization in Patients with Hepatocellular Carcinoma. Liver Cancer,1(1):41–50. Lin CL, Hsieh CF, Chen T, Lin TJ, Huang TC, Lee HC, Chen KY, Liao LY, Wang CK, 2014. Risk factors for 1-year mortality in patients with intermediate-stage hepatocellular vcarcinoma treated solely with transcatheter arterial chemoembolization. Advances in Digestive Medicine, 1: 126e131. Llovet JM, 2005. Updated treatment approach to hepatocellular carcinoma. Journal of Gastroenterology, 40(3):225-35. Llovet JM, Forner A, Bruix J, 2012. Hepatocellular carcinoma. Lancet, 379(9822):1245-55. Lo CH, Liu MY, Lee MS, Yang JF, Jen YM, Lin CS, 2017. Comparison between Child-Turcotte-Pugh and albumin-bilirubin scores in assessing the prognosis of hepatocellular carcinoma after stereotactic ablative radiotherapy. International Journal Radiatherapy Oncology Biology Physiology, 99(1):145-52. Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, and Lewis W, Teperman, 2013. Long-Term Management of the Successful Adult Liver. KARYA AKHIR. SKALA ALBUMIN-BILIRUBIN.... ANDRI PRAMANA RESTU.

IR - PERPUSTAKAAN UNIVERSITAS AIRLANGGA. 62. Transplant: 2012 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transplantation, 19:3-26. Mittal S, dan El-Serag HB, 2013. Epidemiology of hepatocellular carcinoma: consider the population. Journal of Clinical Gastroenterology, 47 Suppl:S2-6. Nakajima T, Nakashima T, Yamaoka J, Shibuya A, Konishi E, Okada Y, Jo M, Nishikawa T, Itoh Y, Yoshikawa T, 2011. Greater age and hepatocellular aging are independent risk factors for hepatocellular carcinoma arising from non-B non-C non-alcoholic chronic liver disease. Pathology International, 61(10):572-6. Namita RC dan Jayanta RC, 2016. Bilirubin metabolism. Uptodate [Online]. Tersedia di: https://www.uptodate.com/contents/bilirubin-metabolism#H4 [Diakses: 26 Juli 2018]. Njei B, Rotman Y, Ditah I, Lim JK, 2015. Emerging Trends in Hepatocellular Carcinoma Incidence and Mortality. Hepatology, 61(1):191–199. Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Azemoto R, Shinozaki M, Yoshikawa M, Yokosuka O, 2015. A Prognostic Score for Patients with Intermediate-Stage Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. PLoS ONE, 10(4): e0125244. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M, 2015. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver International, 35(9):2155-66. Perhimpunan Peneliti Hati Indonesia, 2017. Konsensus Nasional Penatalaksanaan Karsinoma Sel Hati. Jakarta: PPHI. Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS, 2016. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. Journal of Clinical Oncology, 34(15):1787–94. Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, Bettinger D, Jang JW, Smirne C, Kim YW, Kudo M, Howell J, Ramaswami R, Burlone M.E, Guerra V, Thimme R, Ishizuka M, Stebbing J, Pirisi M, Carr BI, 2016. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma, Journal of Hepatology, 66(2):338-46. Pincus MR, Tierno PM, Fenelus M, Bowne WB, Bluth MH, 2011. Evaluation of Liver Function. Dalam: McPherson RA, dan Pincus MR (eds) Henry’s Clinical Diagnosis and Management by Laboratory Methods, edisi 22. Philadelphia: Saunders, pp. 296-311.. KARYA AKHIR. SKALA ALBUMIN-BILIRUBIN.... ANDRI PRAMANA RESTU.

IR - PERPUSTAKAAN UNIVERSITAS AIRLANGGA. 63. Piscaglia F, dan Ogasawara S, 2018. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer, 7(1):104-19. Prajapati HJ, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, 2012. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Annals of Oncology, 24(4):965-73. Pramudya D, 2016. Prediktor kejadian non-responder pada pasien karsinoma hepatoseluler yang dilakukan tindakan TACE. Karya Akhir Program Pendidikan Dokter Spesialis Ilmu Penyakit Dalam, Universitas Airlangga, Surabaya, Indonesia. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R, 2011. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treatment Reviews, 37(3):212-20. Sawhney S, Montano-Loza AJ, Salat P, McCarthy M, Kneteman N, Meza-Junco J, Owen R. Transarterial chemoembolization in patients with hepatocellular carcinoma: predictors of survival. Canadian Journal of Gastroenterology. 2011 Aug;25(8):426-32. Schulze K, Nault JC, Villanueva A, 2016. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. Journal of Hepatology, 65:1031– 42. Schwartz JM, dan Carithers RL, 2017. Clinical features and diagnosis of primary hepatocellular carcinoma. Uptodate [Online]. Tersedia di: https://www.uptodate.com/contents/clinical-features-and-diagnosis-of-primaryhepatocellular-carcinoma [Diakses pada 27 Juli 2018] Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD, 2009. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Reviews of Gastroenterology and Hepatology, 3(4):353-67. Sherman M, 2014. Surveillance for hepatocellular carcinoma. Best Practice & Research: Clinical Gastroenterology, 28:783–93. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K, 2012. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. American Journal of Gastroenterology, 107(4):569-77.. KARYA AKHIR. SKALA ALBUMIN-BILIRUBIN.... ANDRI PRAMANA RESTU.

IR - PERPUSTAKAAN UNIVERSITAS AIRLANGGA. 64. Shin SW, 2009. The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma. Korean Journal of Radiology,10:42534. Sieghart W, Hucke F, Peck-Radosavljevic M, 2015. Transarterial chemoembolization: Modalities, indication, and patient selection. Journal of Hepatology, 62(5):1187–95. Singal AG, Nehra M, Adams-Huet B, 2013. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? American Journal of Gastroenterology, 108: 425–32. Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W, 2012. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver International, 32(7):105363. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A, 2015. Global cancer statistics, 2012. CA: a cancer journal for clinicians, 65(2):87–108. Waked I , Berhane S, Toyoda H, Chan SL, Stern N, Palmer D, Tada T, Yeo W, Mo F, Bettinger D, Kirstein MM, Inarrairaegui M, Gomaa A, Vogel A, Meyer T, Sangro B, Lai P, Kumada T, Johnson PJ, 2017. Transarterial chemoembolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. British Journal of Cancer, 116:448–54. Yau T, Tang VYF, Yao T-J, Fan S-T, Lo C-M, Poon RTP, 2014. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology, 146:1691–700.e3.. KARYA AKHIR. SKALA ALBUMIN-BILIRUBIN.... ANDRI PRAMANA RESTU.